Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
Tj5wv5X2Rmww30pw
